Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.

@article{Rees1999BecaplerminGI,
  title={Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.},
  author={Riley S. Rees and Martin C. Robson and Janice M Smiell and Barbara H Perry},
  journal={Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society},
  year={1999},
  volume={7 3},
  pages={141-7}
}
Pressure ulcers are associated with significant rates of morbidity and mortality, particularly in the geriatric and spinal cord-injured populations. Newer pharmacologically active therapies include the use of topically applied recombinant human platelet-derived growth factor-BB (becaplermin), the active ingredient in REGRANEX) (becaplermin) Gel 0.01%, which… CONTINUE READING